- Home
- NUVB vs BIT Comparison
NUVB vs BIT Comparison
Compare NUVB & BIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- BIT
- Stock Information
- Founded
- NUVB 2018
- BIT 2013
- Country
- NUVB United States
- BIT United States
- Employees
- NUVB N/A
- BIT N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- BIT Trusts Except Educational Religious and Charitable
- Sector
- NUVB Health Care
- BIT Finance
- Exchange
- NUVB Nasdaq
- BIT Nasdaq
- Market Cap
- NUVB 679.9M
- BIT 574.2M
- IPO Year
- NUVB N/A
- BIT N/A
- Fundamental
- Price
- NUVB $2.10
- BIT $14.31
- Analyst Decision
- NUVB Strong Buy
- BIT
- Analyst Count
- NUVB 5
- BIT 0
- Target Price
- NUVB $8.20
- BIT N/A
- AVG Volume (30 Days)
- NUVB 3.2M
- BIT 92.4K
- Earning Date
- NUVB 05-07-2025
- BIT 01-01-0001
- Dividend Yield
- NUVB N/A
- BIT 9.36%
- EPS Growth
- NUVB N/A
- BIT N/A
- EPS
- NUVB N/A
- BIT N/A
- Revenue
- NUVB $10,957,000.00
- BIT N/A
- Revenue This Year
- NUVB $75.73
- BIT N/A
- Revenue Next Year
- NUVB $440.21
- BIT N/A
- P/E Ratio
- NUVB N/A
- BIT N/A
- Revenue Growth
- NUVB N/A
- BIT N/A
- 52 Week Low
- NUVB $1.54
- BIT $13.65
- 52 Week High
- NUVB $3.97
- BIT $15.97
- Technical
- Relative Strength Index (RSI)
- NUVB 50.80
- BIT 61.33
- Support Level
- NUVB $1.98
- BIT $14.12
- Resistance Level
- NUVB $2.30
- BIT $14.29
- Average True Range (ATR)
- NUVB 0.16
- BIT 0.14
- MACD
- NUVB -0.01
- BIT 0.06
- Stochastic Oscillator
- NUVB 21.43
- BIT 98.59
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About BIT BlackRock Multi-Sector Income Trust of Beneficial Interest
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loan and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.